To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
Overview[ - collapse ][ - ]
Purpose | This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy subjects during six weeks of dosing, as well as evaluating the potential for a pharmacokinetic interaction with metformin. Part A consists of Screening, Treatment (6 weeks) and Follow-up periods. - Part B (conducted at multiple sites) will determine safety, tolerability, and pharmacodynamics (PD) in subjects with Type 2 diabetes (T2D) when co-dosed for six weeks with liraglutide (Victoza). Part B consists of Screening, Run-in (1 week), Stabilization (12 weeks), Treatment (6 weeks) and Follow-up periods. - Part C (conducted at multiple sites) will determine safety, tolerability, and PD in subjects with T2D when co-dosed for 6 weeks with metformin. Part C consists of Screening, Run-in (1 week), Stabilization (12 weeks), Treatment (6 weeks) and Follow-up periods. |
---|---|
Condition | Obesity |
Intervention | Drug: GSK2890457 Drug: Metformin Drug: Placebo Drug: Liraglutide |
Phase | Phase 2 |
Sponsor | GlaxoSmithKline |
Responsible Party | GlaxoSmithKline |
ClinicalTrials.gov Identifier | NCT01725126 |
First Received | November 8, 2012 |
Last Updated | February 14, 2014 |
Last verified | November 2013 |
Tracking Information[ + expand ][ + ]
First Received Date | November 8, 2012 |
---|---|
Last Updated Date | February 14, 2014 |
Start Date | February 2013 |
Estimated Primary Completion Date | September 2013 |
Current Primary Outcome Measures |
|
Current Secondary Outcome Measures |
|
Descriptive Information[ + expand ][ + ]
Brief Title | To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes |
---|---|
Official Title | A Double-blind [Sponsor Unblinded], Randomized, Placebo-controlled, Staggered-parallel Study to Investigate the Safety, Tolerability, and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes |
Brief Summary | This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy subjects during six weeks of dosing, as well as evaluating the potential for a pharmacokinetic interaction with metformin. Part A consists of Screening, Treatment (6 weeks) and Follow-up periods. - Part B (conducted at multiple sites) will determine safety, tolerability, and pharmacodynamics (PD) in subjects with Type 2 diabetes (T2D) when co-dosed for six weeks with liraglutide (Victoza). Part B consists of Screening, Run-in (1 week), Stabilization (12 weeks), Treatment (6 weeks) and Follow-up periods. - Part C (conducted at multiple sites) will determine safety, tolerability, and PD in subjects with T2D when co-dosed for 6 weeks with metformin. Part C consists of Screening, Run-in (1 week), Stabilization (12 weeks), Treatment (6 weeks) and Follow-up periods. |
Detailed Description | Not Provided |
Study Type | Interventional |
Study Phase | Phase 2 |
Study Design | Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment |
Condition | Obesity |
Intervention | Drug: GSK2890457 Provided as powder and capsule. Drug: Metformin Tablet Part A: Single doses on Day 1 and Day 42 orally Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed Part C: Subject continues usual metformin dose throughout study Drug: Placebo Provided as powder and Capsule. Drug: Liraglutide Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only Other Names: Victoza |
Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
Recruitment Status | Completed |
---|---|
Estimated Enrollment | 53 |
Estimated Completion Date | September 2013 |
Estimated Primary Completion Date | September 2013 |
Eligibility Criteria | Inclusion Criteria:Part A (Healthy Subjects) - Subject able to understand and voluntarily provide the consent to participate in the study - 18 - 70 years of age, inclusive, at the time of signing the informed consent and Body Mass Index (BMI) between 18.0 and 35.0 Kilogram (kg) per m^2, inclusive - Understands and is willing, able and likely to be compliant with taking study drug and comply with all study procedures and restrictions - Subject is willing to consume the foods that are part of the standardized breakfast, lunch, and dinner - In good general health with no clinically significant and relevant abnormalities of medical history or physical examination which includes adequate renal function, alanine transaminase (ALT), alkaline phosphatase and bilirubin <=1.5x Upper Limit of Normal (ULN ) - QTcF < 450 millisecond (msec); or QTcF < 480msec for subjects with right Bundle Branch Block - Females must be post-menopausal - Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment - Females who are > 3 months postpartum and who have undergone a surgical sterilization procedure are eligible to participate in consultation with the GSK Medical Monitor Parts B and C (Type 2 Diabetic Subjects) - All the criteria mentioned in Part A except Body Mass Index (BMI) should be between 30.0 and 42.0 kg per m^2 - Diagnosis of T2D for at least 3 months, as defined by the American Diabetes Association - All T2D subjects must meet label recommendations for metformin - For Part B, subjects must be willing to discontinue metformin and replace it with daily liraglutide administered by subcutaneous injection and they must meet label recommendations - No personal history or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Exclusion Criteria: - History of gastrointestinal disease, current or chronic history of liver disease, history of serious, severe or unstable physical or psychiatric illness , significant cardiovascular disease, surgery for weight loss or gastrointestinal surgery within 3 months of screening, any documented or reported eating disorder, uncontrolled hypertension, as evidenced by systolic pressure>160 or diastolic pressure >90 mmHg - Positive test for HIV, Hepatitis B, or Hepatitis C at Screening - Subjects with significant ECG abnormalities - For subjects in Part C (continuing metformin), history of untreated pernicious anemia or who have laboratory parameters suggestive of subclinical megaloblastic anemia - Presence of or symptoms of an active infection - Uncorrected Thyroid Dysfunction - History of chronic or acute pancreatitis - Currently dieting to lose weight including, but not limited to, participation in a program designed to alter body weight within the last 60 days and unwilling to maintain relatively consistent exercise patterns throughout the study - Current or recent history (within one year of screening) of alcohol or other substance abuse - Unable to refrain from the use of non-prescription drugs - Current participation in another clinical study or participation in a clinical study involving an investigational drug within 30 days of the screening visit - History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy - An employee of the sponsor or the study site or members of their immediate family. |
Gender | Both |
Ages | 18 Years |
Accepts Healthy Volunteers | Accepts Healthy Volunteers |
Contacts | Not Provided |
Location Countries | United States |
Administrative Information[ + expand ][ + ]
NCT Number | NCT01725126 |
---|---|
Other Study ID Numbers | 116623 |
Has Data Monitoring Committee | No |
Information Provided By | GlaxoSmithKline |
Study Sponsor | GlaxoSmithKline |
Collaborators | Not Provided |
Investigators | Study Director: GSK Clinical Trials GlaxoSmithKline |
Verification Date | November 2013 |
Locations[ + expand ][ + ]
GSK Investigational Site | Chula Vista, California, United States, 91910 |
---|---|
GSK Investigational Site | Miami, Florida, United States, 33169 |
GSK Investigational Site | Overland Park, Kansas, United States, 66211 |